# Natural Killer (NK) Cell Therapy for B-Cell Malignancies

> **NCT05379647** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 24 (estimated)

## Conditions studied

- B-cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** QN-019a
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine
- **DRUG:** VP-16

## Key facts

- **NCT ID:** NCT05379647
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-04
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05379647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05379647, "Natural Killer (NK) Cell Therapy for B-Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05379647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*